1. "Bone Marrow Transplant"
Formats
  1. Meeting Abstract (1488)
  2. Journal Article (1179)
  3. Review (71)
  4. Research Letter (46)
  5. Book Section (34)
  6. Guidelines (26)
  7. Editorial (23)
  8. Correspondence (17)
  9. Conference Paper (14)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Bone Marrow Transplant (2900)
  2. Center for Hematologic Malignancies (2900)
  3. Department of Medicine (2900)
  4. Hematologic Malignancies, Division of (2777)
  5. Survivorship Research (1345)
  6. GSK Faculty (917)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (914)
  3. Sean Devlin (457)
  4. Ann Jakubowski (456)
  5. Heather Landau (419)
  6. Gunjan Shah (418)

More People

Years
  1. 2025 (40)
  2. 2024 (169)
  3. 2023 (263)
  4. 2022 (201)
  5. 2021 (177)
  6. 2020 (208)

More Years

Publications
  1. Blood (840)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (175)
  4. Journal of Clinical Oncology (125)
  5. Transplantation and Cellular Therapy (110)
  6. Blood Advances (88)

More Publications

Publishers
  1. American Society of Hematology (935)
  2. Elsevier Inc. (762)
  3. Nature Publishing Group (258)
  4. American Society of Clinical Oncology (128)
  5. Wiley Blackwell (65)
  6. Taylor & Francis Group (64)

More Publishers

Results (2900)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M. K.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López Guillermo, A.; Martinez-Lopez, J.; Novak, U.; Ribrag, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting CD47 in lymphoid malignancies with CAR T cells
    Meeting Abstract

    Boardman, A. P.; James, S.; Van Den Brink, M. R. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L. J.; Eradat, H.; Munoz, J.; Tees, M. T.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S.; Popplewell, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save
  • Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Westin, J.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Lenalidomide-associated B-cell ALL: Clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
    Journal Article

    Geyer, M. B.; Shaffer, B. C.; Bhatnagar, B.; Mims, A. S.; Klein, V.; Dilip, D.; Glass, J. L.; Lozanski, G.; Hassoun, H.; Landau, H.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
    Research Letter

    Lin, R. J.; Kim, S. J.; Brown, S.; Elko, T. A.; Ruiz, J. D.; Hanley, D. M.; Palomba, M. L.; Perales, M. A.; Shah, G. L.; Dahi, P. B.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
    Journal Article

    Merrill, M. H.; Dahi, P. B.; Redd, R. A.; McDonough, M. M.; Chen, Y. B.; DeFilipp, Z.; Herrera, A. F.; Fisher, D. C.; LaCasce, A. S.; Odejide, O. O.; more...
    Blood (2023)

    Fulltext@MSK | Save